DYAD raises £7.5m to expand NHS AI rollout and enter new markets

DYAD secures £7.5m Series A led by Sangha Capital

UK healthcare AI company DYAD has secured $10m (£7.5m) in Series A funding to broaden its NHS business and pursue international growth, BusinessCloud reports. The investment gives the company capital to expand beyond its established GP practice customer base.

Sangha Capital led the round, which closed in April 2026 with participation from existing investors. BusinessCloud also named Bill Tai and Carbide Ventures among the technology investors backing the financing.

BetterLetter serves more than 200 GP practices

Dr Alexander Tayler and Dr Steven Hamblin founded DYAD six years ago, according to BusinessCloud. The company addresses the administrative work involved in producing and interpreting clinical documents whose contents cannot readily be transferred into structured digital records.

Its primary care platform, BetterLetter, serves more than 200 GP practices and has handled over five million clinical documents. BusinessCloud puts the annual burden associated with transferring unstructured information between secondary and primary care at £300m — the problem BetterLetter is designed to tackle.

The technology behind BetterLetter is DYAD’s proprietary AI system, GENIE. It converts information from clinical documents into structured data suitable for patient records or tasks that AI agents can carry out, according to the report.

BetterLetter’s clinical coding process includes a human approval stage: a practice team member checks each proposed entry before it is added to a patient record. That makes the product a staff-reviewed workflow rather than an unchecked route from document to record.

DYAD also employs its own clinical coding team. BusinessCloud reports that the team helps the product improve through practical use and address problems encountered within healthcare administration, keeping development connected to the work of clinical coders.

Tayler and Sangha point to specialist technology and demand

Chief executive Tayler described DYAD’s approach as combining a model developed specifically for clinical coding with an agent-based healthcare administration platform, BusinessCloud reported. His position is that the company’s specialist technology can address information that existing healthcare systems struggle to integrate.

Carolina Casas Forga of Sangha Capital cited both the technology’s capabilities and evidence of demand in primary care as reasons for backing DYAD, according to BusinessCloud. She presented that existing business as a basis for applying the company’s tools more widely across healthcare, rather than treating the investment as a bet on an untested product.

Secondary care and mental health are the next targets

DYAD plans to use the proceeds to speed up deployment across UK primary care while adapting its AI for secondary care and mental health services, BusinessCloud reports. Those additional applications are intended for both the NHS and international markets.

Progress notes, referral documents and care planning are among the workflows DYAD intends to address in those settings. The expansion therefore involves applying its document-processing technology to different clinical tasks, not simply selling the same GP product to more practices.

BusinessCloud’s report does not identify overseas launch countries or give a deployment timetable for the new services. For businesses assessing DYAD’s expansion into additional healthcare markets, those details remain open: the financing is complete, but the geographic sequence and timing of the wider rollout have not been specified.